
Sign up to save your podcasts
Or
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2.
4.4
1717 ratings
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2.
32 Listeners
43 Listeners
99 Listeners
5 Listeners
11 Listeners
8 Listeners
20 Listeners
49 Listeners
10 Listeners
1 Listeners
17 Listeners
16 Listeners
0 Listeners
0 Listeners
0 Listeners